What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Acquired immunodeficiency syndrome
- Virus
David A. Cooper mostly deals with Immunology, Internal medicine, Virology, Acquired immunodeficiency syndrome and Viral load.
David A. Cooper interconnects Lipodystrophy, Endocrinology, Surgery, Zidovudine and Gastroenterology in the investigation of issues within Internal medicine.
His work in Lipodystrophy tackles topics such as Lipoatrophy which are related to areas like Outpatient clinic.
David A. Cooper has researched Endocrinology in several fields, including Protease inhibitor and HIV-associated lipodystrophy.
His research investigates the link between Acquired immunodeficiency syndrome and topics such as Cohort study that cross with problems in Cohort.
His study in Viral load is interdisciplinary in nature, drawing from both Clinical trial, Regimen, Adverse effect, Pharmacotherapy and Raltegravir.
His most cited work include:
- Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study (2421 citations)
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. (2105 citations)
- CD4+ count-guided interruption of antiretroviral treatment. (1814 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Immunology, Internal medicine, Virology, Acquired immunodeficiency syndrome and Viral load.
His study in Viral disease, Immune system, Immunopathology, T cell and CD8 is carried out as part of his studies in Immunology.
His Internal medicine research integrates issues from Gastroenterology, Surgery and Zidovudine.
His studies in Virology integrate themes in fields like Cytotoxic T cell, Antibody and Antigen.
In his research, Cohort study is intimately related to Cohort, which falls under the overarching field of Acquired immunodeficiency syndrome.
In his study, Integrase inhibitor is strongly linked to Raltegravir, which falls under the umbrella field of Viral load.
He most often published in these fields:
- Immunology (41.78%)
- Internal medicine (36.90%)
- Virology (30.31%)
What were the highlights of his more recent work (between 2012-2021)?
- Immunology (41.78%)
- Internal medicine (36.90%)
- Virology (30.31%)
In recent papers he was focusing on the following fields of study:
His main research concerns Immunology, Internal medicine, Virology, Viral load and Randomized controlled trial.
Immunology is often connected to Cohort in his work.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Raltegravir, Pharmacology and Ritonavir.
David A. Cooper combines subjects such as Antibody and Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019 with his study of Virology.
His work in Viral load addresses issues such as Proportional hazards model, which are connected to fields such as Hazard ratio.
His Randomized controlled trial research includes themes of Physical therapy and Adverse effect.
Between 2012 and 2021, his most popular works were:
- Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study (2421 citations)
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. (387 citations)
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. (341 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Acquired immunodeficiency syndrome
- Cancer
David A. Cooper spends much of his time researching Immunology, Virology, Internal medicine, Viral load and Randomized controlled trial.
His Immunology course of study focuses on Cohort and Cd4 cell count.
His Virology research includes elements of Epitope, Reverse transcriptase, B cell and Severe acute respiratory syndrome coronavirus 2.
The various areas that David A. Cooper examines in his Internal medicine study include Raltegravir, Placebo and Pharmacology.
He works mostly in the field of Pharmacology, limiting it down to concerns involving Efavirenz and, occasionally, Pharmacokinetics and Gastroenterology.
His work carried out in the field of Viral load brings together such families of science as Young adult, Demography, Proportional hazards model, Seroconversion and Emtricitabine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
